UNSPSC 51171824: Bemesetron

This classification denotes a 5-ht3 receptor antagonist with the molecular formula C15H17Cl2NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O98T3677PA, chemically known as 3-tropanyl-3,5-dichlorobenzoate but generally known as bemesetron, which bears US NIH Compound Identifier 1683. European Medicines Agency schedules Bemesetron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05692MIG.

UNSPSC 51171824 Bemesetron, a Commodity code, covers drug-testing and specimen-collection services and pharmaceutical products supplied to state and local public bodies. State and local governments are soliciting under this code for offender drug-testing services (immunoassay screening with confirmatory testing via LC/MS/MS or GC/MS, oral fluid and hair testing), generic pharmaceuticals and over-the-counter products for distribution through authorized wholesalers, and direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers. Issuing bodies include county community supervision and corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts for state and local government facilities and employee health plans.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026, due July 23, 2026, seeking offender specimen collection and drug testing services to operate collection sites in Plano and McKinney, process approximately 25,031 annual tests using immunoassay screening with confirmatory analysis, maintain SAMHSA or Texas DPS lab certification, and staff two facilities five days per week plus five Saturdays annually; the estimated contract value is $600,000 over two years with three optional one-year renewal periods, and award is anticipated August 10, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with products effective July 1, 2026; evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, pricing format, and administrative-fee adherence. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program seeking vendors experienced in direct contracting with self-insured employers and state agencies outside traditional pharmacy benefit managers.